BRVT121

BRVT121 is a small molecule drug candidate developed by Biorevert. It is being investigated as a novel anti-cancer therapy with the innovative concept of reprogramming cancer cells into normal cells, rather than directly killing them. This approach aims to manage cancer as a chronic disease without the side effects typically associated with cytotoxic therapies, potentially maximizing healthy lifespan for patients. The targets for BRVT121 were discovered by Professor Kwang-Hyun Cho's group at KAIST and represent first-in-class mechanisms in oncology research. The primary indication under investigation is hepatocellular carcinoma, and it may also have potential applications in other neoplasms and digestive system disorders[1][5].